|Most Popular Apple's Decade: How It Can Hit $500|
|Most Commented Biotech Stock Mailbag: FDA Playbook|
Cramer shares his views on how tired he is of hearing about Kool-Aid, and wonders if Apple could be valued as a consumer-products company one day.
Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.
The tech giant's reported plans to produce the low-cost iPhone model in India would allow it to avoid important tariffs and possibly obtain lower labor costs.
The tech giant is surprisingly not too far away from the magic number.